RU2014127074A - Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы - Google Patents

Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы Download PDF

Info

Publication number
RU2014127074A
RU2014127074A RU2014127074A RU2014127074A RU2014127074A RU 2014127074 A RU2014127074 A RU 2014127074A RU 2014127074 A RU2014127074 A RU 2014127074A RU 2014127074 A RU2014127074 A RU 2014127074A RU 2014127074 A RU2014127074 A RU 2014127074A
Authority
RU
Russia
Prior art keywords
composition
emulsion
composition according
dry eye
castor oil
Prior art date
Application number
RU2014127074A
Other languages
English (en)
Russian (ru)
Inventor
Джозеф Дж. ВЕИДЖ
Питер А. СИММОНС
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2014127074(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2014127074A publication Critical patent/RU2014127074A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014127074A 2011-12-07 2012-12-07 Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы RU2014127074A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US61/568,089 2011-12-07
US201261625401P 2012-04-17 2012-04-17
US61/625,401 2012-04-17
PCT/US2012/068615 WO2013086449A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018119362A Division RU2772357C2 (ru) 2011-12-07 2012-12-07 Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы

Publications (1)

Publication Number Publication Date
RU2014127074A true RU2014127074A (ru) 2016-02-10

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014127074A RU2014127074A (ru) 2011-12-07 2012-12-07 Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы

Country Status (27)

Country Link
US (2) US9314528B2 (enExample)
EP (5) EP2787969B1 (enExample)
JP (1) JP6142419B2 (enExample)
KR (1) KR102017922B1 (enExample)
CN (2) CN108969482A (enExample)
AR (1) AR089123A1 (enExample)
AU (2) AU2012347459A1 (enExample)
BR (1) BR112014013820A2 (enExample)
CA (1) CA2858574C (enExample)
CL (1) CL2014001518A1 (enExample)
CO (1) CO6990739A2 (enExample)
DK (2) DK2787968T3 (enExample)
ES (2) ES2896336T3 (enExample)
HU (2) HUE057140T2 (enExample)
IL (1) IL233008A (enExample)
IN (1) IN2014CN04809A (enExample)
MX (1) MX355216B (enExample)
MY (1) MY173378A (enExample)
PH (2) PH12021553172A1 (enExample)
PL (2) PL2787968T3 (enExample)
PT (2) PT2787968T (enExample)
RU (1) RU2014127074A (enExample)
SG (1) SG11201403013VA (enExample)
SI (2) SI2787969T1 (enExample)
TW (1) TWI652072B (enExample)
WO (2) WO2013086449A1 (enExample)
ZA (1) ZA201404228B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
LT3266446T (lt) 2016-07-07 2019-01-25 Laboratorios Salvat, S.A. Oftalmologinė kompozicija, apimanti ricinos aliejų ir vidutinio grandinės ilgio trigliceridą
JP2019524892A (ja) 2016-08-19 2019-09-05 アクリビスタ エルエルシーAkrivista,Llc ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
WO2019036625A1 (en) * 2017-08-18 2019-02-21 Akrivista, LLC METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE
TW202014194A (zh) 2018-04-27 2020-04-16 美商歐樂根公司 抗微生物功效增強且毒性降低之亞氯酸鈉組成物
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
EP0028110B1 (en) * 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
CA2037057C (en) 1989-08-03 1995-03-21 Takakazu Morita Photostabilizing method for ophthalmic solutions and the resulting opthalmic solutions therefrom
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
AU1295200A (en) 1998-11-13 2000-06-05 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
EP1301210A2 (en) 2000-07-14 2003-04-16 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
ATE443749T1 (de) 2000-11-08 2009-10-15 Fxs Ventures Llc Verbesserte ophthalmische und kontaktlinsenlösungen mit einfachen sacchariden als konservierungsverbesserer
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
WO2004028536A1 (en) 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
EP1551417B1 (en) * 2002-10-18 2008-09-10 Joel S. Echols Three layer tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
KR20110134525A (ko) * 2003-06-13 2011-12-14 알콘, 인코퍼레이티드 시너지성의 2개의 폴리머 배합물을 포함하는 안과용 조성물
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US20070077278A1 (en) * 2003-11-10 2007-04-05 Yukiko Sugihara Polysaccharide-containing composition and tear film stabilizing ophthalmic solution
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
EP2437762B1 (en) 2009-06-05 2017-08-09 Allergan, Inc. Artificial tears and therapeutic uses
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
ES2797650T3 (es) 2020-12-03
HK1201458A1 (en) 2015-09-04
CO6990739A2 (es) 2014-07-10
CN104114152A (zh) 2014-10-22
TWI652072B (zh) 2019-03-01
SG11201403013VA (en) 2014-07-30
AR089123A1 (es) 2014-07-30
EP2787968B1 (en) 2020-03-04
HUE049489T2 (hu) 2020-09-28
IL233008A (en) 2017-07-31
EP2787969B1 (en) 2021-09-29
DK2787968T3 (da) 2020-06-02
PH12014501296A1 (en) 2014-10-08
PL2787969T3 (pl) 2021-12-20
JP2015504860A (ja) 2015-02-16
BR112014013820A8 (pt) 2017-06-13
KR102017922B1 (ko) 2019-09-03
AU2017265181B2 (en) 2019-06-20
PH12014501296B1 (en) 2023-04-05
HK1203057A1 (en) 2015-10-16
SI2787969T1 (sl) 2021-12-31
CN108969482A (zh) 2018-12-11
PT2787968T (pt) 2020-06-16
CA2858574A1 (en) 2013-06-13
MY173378A (en) 2020-01-21
US20130150324A1 (en) 2013-06-13
RU2018119362A3 (enExample) 2021-09-07
IL233008A0 (en) 2014-07-31
KR20140107383A (ko) 2014-09-04
PT2787969T (pt) 2021-11-09
TW201325633A (zh) 2013-07-01
US20130197083A1 (en) 2013-08-01
EP4403220A2 (en) 2024-07-24
AU2012347459A1 (en) 2014-07-03
MX355216B (es) 2018-04-10
SI2787968T1 (sl) 2020-08-31
EP4403220A3 (en) 2024-10-23
CL2014001518A1 (es) 2014-10-24
IN2014CN04809A (enExample) 2015-09-18
WO2013086449A1 (en) 2013-06-13
JP6142419B2 (ja) 2017-06-07
US9314528B2 (en) 2016-04-19
EP3666257A1 (en) 2020-06-17
RU2018119362A (ru) 2018-11-08
MX2014006804A (es) 2014-09-22
EP3981387A1 (en) 2022-04-13
DK2787969T3 (da) 2021-11-01
BR112014013820A2 (pt) 2017-06-13
HUE057140T2 (hu) 2022-04-28
ES2896336T3 (es) 2022-02-24
ZA201404228B (en) 2015-12-23
EP2787968A1 (en) 2014-10-15
EP2787969A1 (en) 2014-10-15
WO2013086438A1 (en) 2013-06-13
PL2787968T3 (pl) 2020-08-24
AU2017265181A1 (en) 2017-12-14
PH12021553172A1 (en) 2024-05-27
CA2858574C (en) 2017-05-30

Similar Documents

Publication Publication Date Title
RU2014127074A (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
EA201792559A1 (ru) Фармацевтические композиции для местного применения
RU2014122945A (ru) Композиции для лечения сухости глаза
EA201291108A1 (ru) Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
RU2013112353A (ru) Фосфолипидный депо-препарат
JP2015504860A5 (enExample)
MX349169B (es) Composiciones farmaceuticas oftalmicas y metodos para elaborar y usar las mismas.
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
RU2017134440A (ru) Композиции для местного применения, содержащие кортикостероид
RU2015109566A (ru) НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА
PH12019500970A1 (en) Composition for the treatment and/or prevention of the black sigatoka fungal disease in banana crops
RU2019139886A (ru) Терапевтическое средство против дисфункции мейбомиевых желез
RU2016129193A (ru) Составы на основе берберина и их применение
EA201291335A1 (ru) Фармацевтические композиции для местного применения
BR112017014016A2 (pt) método de redução da pressão intraocular, e, composição farmacêutica.
AR055591A1 (es) Una composicion topica protectora de la piel y su uso
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
MX2023004516A (es) Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
RU2013137782A (ru) Водный ионный раствор, содержащий морскую воду, по меньшей мере одно соединение, изначально не смешивающееся с морской водой
RU2013105211A (ru) ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Arg-Pro-Gly-Pro В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
RU2017142726A (ru) Офтальмическая композиция, содержащая липоевую кислоту и мукомиметический полимер
RU2010153203A (ru) Смягчающая композиция для превентивного воздействия при атопическом дерматите